Daxor Corporation Announces $9 Million Registered Direct Offering
Rhea-AI Summary
Daxor (NasdaqCM: DXR) entered a definitive agreement for a registered direct offering of 765,958 shares at $11.75 per share, expected to close on or about January 26, 2026. Gross proceeds are expected to be approximately $9 million before placement agent fees and offering expenses. The company intends to use net proceeds for general corporate purposes, including working capital. Lake Street Capital Markets is the exclusive placement agent. The related Form N-2 registration was declared effective on January 20, 2026. The offering will be made only by prospectus supplement and accompanying prospectus and will be filed with the SEC.
Positive
- Gross proceeds of approximately $9 million
- Definitive agreement executed to sell 765,958 shares
- Registration declared effective on January 20, 2026
- Exclusive placement agent: Lake Street Capital Markets
Negative
- Issuance of 765,958 shares may dilute existing shareholders
- Net proceeds reduced by placement agent fees and offering expenses
- Closing subject to customary conditions; expected close on Jan 26, 2026 is not guaranteed
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: AKYA -8.51%, ZJYL +7.13%, ZTEK +3.19%, PDEX -0.46%, MLSS +8.96%, indicating stock-specific context for DXR’s equity offering.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Commercial expansion | Positive | -1.9% | Expansion of BVA platform into three new healthcare facilities. |
| Oct 21 | Investor conference | Neutral | +2.0% | CEO meetings with institutional investors at Maxim Growth Summit. |
| Oct 15 | Product showcase | Positive | -1.0% | Debut of next‑generation BVA diagnostic system at MedAxiom event. |
| Sep 30 | Clinical and product | Positive | +6.2% | Unveiling FDA‑cleared BVA analyzer and pivotal clinical data at HFSA. |
| Sep 23 | Product launch | Positive | +3.3% | Announcement of next‑gen BVA analyzer with faster, lower‑volume testing. |
Product and clinical milestones often saw positive price alignment, while some commercial expansion updates drew negative reactions.
Over the last several months, Daxor emphasized growth of its Blood Volume Analysis platform, including new facility adoptions and ezBVA lab services on Nov 25, 2025, along with showcasing next‑generation BVA technology at major cardiovascular meetings in September–October 2025. FDA‑cleared next‑gen analyzer announcements and pivotal data at HFSA on Sep 30, 2025 coincided with a 6.21% gain, while earlier product showcase news on Sep 23, 2025 aligned with a 3.33% rise. Today’s registered direct offering follows this phase of commercialization and clinical validation.
Market Pulse Summary
This announcement details a registered direct offering of 765,958 shares at $11.75, for expected gross proceeds of about $9 million before expenses, to fund general corporate purposes and working capital. It follows recent product and clinical milestones for Daxor’s BVA platform and coincides with related 424B3 and 8‑K filings. Investors may monitor how efficiently the new funds are deployed and how this financing fits alongside ongoing commercialization and regulatory objectives.
Key Terms
registered direct offering financial
placement agent financial
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of
The gross proceeds from the offering to the Company are expected to be approximately
Lake Street Capital Markets, LLC is acting as the exclusive placement agent for the offering.
A registration statement on Form N-2 (File Nos. 333-281622 and 881-22684) relating to the shares of common stock being offered was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 16, 2024 and declared effective on January 20, 2026. The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering, when filed, may be obtained on the SEC’s website at www.sec.gov or by contacting Lake Street Capital Markets, LLC, 121 S 8th Street, Suite 1000, Minneapolis, Minnesota 55402.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Daxor Corporation
Daxor is tackling healthcare’s “multi-billion-dollar silent crisis”, the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
Forward Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
212-655-0924
FAQ
What is the size and price of the Daxor (DXR) registered direct offering announced January 23, 2026?
When is the Daxor (DXR) offering expected to close and what conditions apply?
How does Daxor (DXR) plan to use the proceeds from the $9 million offering?
Who is the placement agent for Daxor (DXR)’s registered direct offering?
Where can investors find the prospectus for the Daxor (DXR) offering?
